Cargando…

Selection of opioids for cancer-related pain using a biomarker: a randomized, multi-institutional, open-label trial (RELIEF study)

BACKGROUND: Cancer patients experience pain that has physiological, sensory, affective, cognitive, behavioral, and sociocultural dimensions. Opioids are used in treatment of pain in patients with various types of cancer. We previously showed that the catechol-O-methyltransferase (COMT) genotype is r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Matsuoka, Hiromichi, Tsurutani, Junji, Chiba, Yasutaka, Fujita, Yoshihiko, Terashima, Masato, Yoshida, Takeshi, Sakai, Kiyohiro, Otake, Yoichi, Koyama, Atsuko, Nishio, Kazuto, Nakagawa, Kazuhiko
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Study Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5639590/ https://www.ncbi.nlm.nih.gov/pubmed/28985716 http://dx.doi.org/10.1186/s12885-017-3664-z

Ejemplares similares

Incidence of carnitine deficiency in patients with cancer pain: A pilot study
por: Sakai, Kiyohiro, et al.
Publicado: (2017)

Morphine Versus Oxycodone for Cancer Pain Using a Catechol-O-methyltransferase Genotype Biomarker: A Multicenter, Randomized, Open-Label, Phase III Clinical Trial (RELIEF Study)
por: Matsuoka, Hiromichi, et al.
Publicado: (2022)

Expectation of a Decrease in Pain Affects the Prognosis of Pain in Cancer Patients: a Prospective Cohort Study of Response to Morphine
por: Matsuoka, Hiromichi, et al.
Publicado: (2017)

Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer pain
por: Fujita, Yoshihiko, et al.
Publicado: (2023)

Regression of brain metastases from breast cancer with eribulin: a case report
por: Matsuoka, Hiromichi, et al.
Publicado: (2013)

Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing
por: Sakai, Kazuko, et al.
Publicado: (2015)

HER2 genomic amplification in circulating tumor DNA and estrogen receptor positivity predict primary resistance to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer
por: Sakai, Hitomi, et al.
Publicado: (2018)

Synergistic antitumor effects of S-1 with eribulin in vitro and in vivo for triple-negative breast cancer cell lines
por: Terashima, Masato, et al.
Publicado: (2014)

Gender differences in cancer-related distress in Japan: a retrospective observation study
por: Koyama, Atsuko, et al.
Publicado: (2016)

Avoiding diagnostic errors in psychosomatic medicine: a case series study
por: Koyama, Atsuko, et al.
Publicado: (2018)

The physical and psychological problems of immigrants to Japan who require psychosomatic care: a retrospective observation study
por: Koyama, Atsuko, et al.
Publicado: (2016)

KIAA1199 interacts with glycogen phosphorylase kinase β-subunit (PHKB) to promote glycogen breakdown and cancer cell survival
por: Terashima, Masato, et al.
Publicado: (2014)

Clinical and immune profiling for cancer of unknown primary site
por: Haratani, Koji, et al.
Publicado: (2019)

Sensitivities to various epidermal growth factor receptor‐tyrosine kinase inhibitors of uncommon epidermal growth factor receptor mutations L861Q and S768I: What is the optimal epidermal growth factor receptor‐tyrosine kinase inhibitor?
por: Banno, Eri, et al.
Publicado: (2016)

Efficacy of irreversible EGFR-TKIs for the uncommon secondary resistant EGFR mutations L747S, D761Y, and T854A
por: Chiba, Masato, et al.
Publicado: (2017)

Hypoxia induces resistance to ALK inhibitors in the H3122 non-small cell lung cancer cell line with an ALK rearrangement via epithelial-mesenchymal transition
por: KOGITA, AKIHIRO, et al.
Publicado: (2014)

MEK inhibitors against MET-amplified non-small cell lung cancer
por: Chiba, Masato, et al.
Publicado: (2016)

Mutational activation of the epidermal growth factor receptor down‐regulates major histocompatibility complex class I expression via the extracellular signal‐regulated kinase in non–small cell lung cancer
por: Watanabe, Satomi, et al.
Publicado: (2018)

FGFR gene alterations in lung squamous cell carcinoma are potential targets for the multikinase inhibitor nintedanib
por: Hibi, Masaaki, et al.
Publicado: (2016)

Successful long-term treatment of non–small cell lung cancer positive for RET rearrangement with pemetrexed
por: Takeda, Masayuki, et al.
Publicado: (2019)

Combined Analysis of Plasma Amphiregulin and Heregulin Predicts Response to Cetuximab in Metastatic Colorectal Cancer
por: Yonesaka, Kimio, et al.
Publicado: (2015)

Melanoma Transition Is Frequently Accompanied by a Loss of Cytoglobin Expression in Melanocytes: A Novel Expression Site of Cytoglobin
por: Fujita, Yoshihiko, et al.
Publicado: (2014)

Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer
por: Sakai, Kazuko, et al.
Publicado: (2015)

Clinical outcome of node‐negative oligometastatic non–small cell lung cancer
por: Sakai, Kiyohiro, et al.
Publicado: (2016)

HER2 genomic amplification in circulating tumor DNA from patients with cetuximab-resistant colorectal cancer
por: Takegawa, Naoki, et al.
Publicado: (2015)

Multiple regulatory mechanisms of hepatocyte growth factor expression in malignant cells with a short poly(dA) sequence in the HGF gene promoter
por: SAKAI, KAZUKO, et al.
Publicado: (2015)

Homozygous deletion of the activin A receptor, type IB gene is associated with an aggressive cancer phenotype in pancreatic cancer
por: Togashi, Yosuke, et al.
Publicado: (2014)

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
por: Sakai, Kazuko, et al.
Publicado: (2019)

New Era for Next-Generation Sequencing in Japan
por: Takeda, Masayuki, et al.
Publicado: (2019)

Efficacy of Crizotinib After Entrectinib Resistance Due to MET Polysomy in ROS1-Rearranged NSCLC: A Case Report
por: Takakura, Toshiaki, et al.
Publicado: (2023)

Heregulin-expressing HER2-positive breast and gastric cancer exhibited heterogeneous susceptibility to the anti-HER2 agents lapatinib, trastuzumab and T-DM1
por: Nonagase, Yoshikane, et al.
Publicado: (2016)

Increased risk of SSEs in bone-only metastatic breast cancer patients treated with zoledronic acid
por: Yanae, Masashi, et al.
Publicado: (2017)

Chemotherapy-induced peripheral neuropathy in breast cancer patients treated with eribulin: interim data from a post-marketing observational study
por: Tsurutani, Junji, et al.
Publicado: (2018)

Frequent amplification of ORAOV1 gene in esophageal squamous cell cancer promotes an aggressive phenotype via proline metabolism and ROS production
por: Togashi, Yosuke, et al.
Publicado: (2013)

Clinical utility of erlotinib for the treatment of non-small-cell lung cancer in Japanese patients: current evidence
por: Togashi, Yosuke, et al.
Publicado: (2014)

Feasibility study of two schedules of sunitinib in combination with pemetrexed in patients with advanced solid tumors
por: Okamoto, Isamu, et al.
Publicado: (2010)

Impact of ramucirumab plus erlotinib on circulating cell-free DNA from patients with untreated metastatic non-small cell lung cancer with EGFR-activating mutations (RELAY phase 3 randomized study)
por: Nishio, Kazuto, et al.
Publicado: (2023)

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
por: Yonesaka, Kimio, et al.
Publicado: (2019)

Endogenous opioids contribute to the feeling of pain relief in humans
por: Sirucek, Laura, et al.
Publicado: (2021)

Study protocol for a multi-institutional, randomised, double-blinded, placebo-controlled phase III trial investigating additive efficacy of duloxetine for neuropathic cancer pain refractory to opioids and gabapentinoids: the DIRECT study
por: Matsuoka, Hiromichi, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_7r8f6ekmjqgjtgadqjea2c96da